Enoximone in status asthmaticus. Issue 1 (6th April 2020)

• Record Type: Journal Article
• Authors: Schulz, Oscar; Wiesner, Olaf; Welte, Tobias; Bollmann, Benjamin-Alexander; Suhling, Hendrik; Hoeper, Marius M.; Busch, Markus
• Is Part Of: ERJ open research. Volume 6:Issue 1(2020)
• Publication Date: 2020-04-06
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; Respiration; Respiratory organs -- Diseases; Respiratory organs -- Diseases -- Treatment; Respiratory Tract Diseases; Electronic journals; Fulltext; Internet Resources; Periodicals; Periodical; 616.2005
• DOI: 10.1183/23120541.00367-2019
• Languages: English
• ISSNs: 2312-0541

Abstract

Bronchial asthma is a chronic disease affecting >300 million people worldwide [1]. The most severe disease manifestation is status asthmaticus, which can be unresponsive to medical therapy. Patients with severe status asthmaticus who require intubation and mechanical ventilation have mortality rates of up to 20% [2]. Airflow obstruction is often so severe that adequate decarboxylation and protective ventilation are not feasible, and extracorporeal membrane oxygenation (ECMO) support is nowadays an established treatment option as a bridge to recovery [3, 4]. In a patient with severe status asthmaticus, enoximone, a phosphodiesterase-3 inhibitor, caused immediate bronchodilation http://bit.ly/38UYpUn